undamentalytics Newsletter
Sign in

Teleflex Inc (TFX) stock

Add to watchlist

Add holding +

NYSE: TFX NYSE Health Care Equipment Next results ~November 5, 2026

B Fundamentals grade

Teleflex Inc is a US-listed company in the health care equipment industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: after-tax interest is 69% of the cash flow left for shareholders; our flat discount rate doesn't yet reflect debt this heavy.

Price vs value

Under review: after-tax interest is 69% of the cash flow left for shareholders; our flat discount rate doesn't yet reflect debt this heavy. We'll show the comparison once resolved.

Teleflex Inc valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds190 adding, 180 cuttingOf 60 active managers that changed their stake, 30 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Teleflex files

Where Teleflex stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $2.25bn, up 30.7% on a year earlier, faster than 25.0% a quarter earlier. That growth ranks 91 of 931 among all the companies we cover. Free-cash-flow margin rose to 7.5% from 1.1% a year earlier. Operating margin narrowed to 2.0% from 16.9%. The diluted share count is down 4.0% on a year earlier, which lifts each remaining share. Against its peers on growth, profitability, cash generation and balance sheet, it grades C+. It passes 1 of our 7 financial-health checks.

Our model value for Teleflex is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 6, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 5, 2026 (estimated)

Teleflex Inc's trailing-twelve-month revenue grew 30.7% year on year, with a free-cash-flow margin of 7.5%. Where it stands out: change in share count of -4.0% ranks 9 of 115 health care equipment companies we cover.

Our discounted-cash-flow model values the business at ~$57 per share in the base case (~$29–$95 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Revenue growth accelerating: TTM revenue growth rose to 30.7% (+5.7pp vs the prior quarter).

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 30.7% over the last 12 months, against a median of 9.1% for health care equipment companies we cover.
  • Growth speeding up. The growth rate is 5.7 points higher than a quarter earlier.
  • Shrinking share count. Diluted shares fell 4.0% in a year, so each share owns more of the business.

Things to watch

  • Margins narrowing. Operating margin is down 14.9 points on a year ago.
  • Gross margin slipping. Gross margin is down 5.9 points on a year ago.
  • Below peers: long-term debt as % of assets. Long-term debt as % of assets of 40.1% ranks 69 of 87 health care equipment companies we cover (median 24.2%).
  • Heavily shorted. 15.6% of the shares available to trade are sold short (5.0 days of average volume to cover).

Latest results: FY2026 Q2

Filed August 6, 2026
Earnings per share
$1.76 against an average estimate of $1.28: beat by 37.4%
Revenue
$570m, up 28.9% on a year earlier
Share reaction
-1.3% in the first session after the results on August 6, 2026, against +0.5% for the S&P 500
Guidance given
GAAP revenue growth from continuing operations growth 13.4% to 14.4% (full year 2026); pro forma adjusted constant currency revenue growth from continuing operations growth 3.5% to 4.5% (full year 2026)
Next report
November 5, 2026; average EPS estimate $1.89

Teleflex's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+0.6%
  • 1 week+2.8%
  • 1 month+13.3%
  • This year+16.2%
  • 1 year+14.3%
  • 5 years-58.0%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$2.3B
Operating margin
2.0%
Net margin
-45.8%
EPS (TTM, diluted)
$-23.37

Growth

Revenue growth
+30.7%
Change in growth rate
+5.7 pts
Share count change
−4.0%

Cash

Free cash flow (TTM)
$168M
FCF margin
7.5%
Stock pay % of revenue
1.1%

Earnings

Last results
August 6, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Regulatory
  2. Announcement
  3. Announcement
  4. Leadership
  5. Leadership
  6. Announcement
  7. Announcement
  8. Dividend
  9. Results
  10. Guidance
  11. Announcement
  12. Deal
  13. Regulatory

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Teleflex Inc valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: held for review: after-tax interest is 69% of the cash flow left for shareholders; our flat discount rate doesn't yet reflect debt this heavy.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Teleflex Inc as an operating company, with every model that fits that kind of business. Cost of equity 8.7%: the 10-year Treasury yield (4.9%) plus a beta of 0.84 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. — Does not apply: This model is withheld pending its input or assumption review.
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. — Does not apply: This model is withheld pending its input or assumption review.
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$180 ~$160–$290 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. ~$23 ~$13–$36 Left out: out of range vs price (0.16x)
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. ~$7.0 ~$6.3–$7.9 Left out: out of range vs price (0.05x)
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Teleflex Inc with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025Now
Share price$122.69$151.72$235.79$246.28$360.21$395.34$316.69$241.91$243.08$174.63$121.07$140.67
Market value$5.9bn$7.2bn$11.0bn$11.5bn$17.0bn$18.7bn$15.0bn$11.4bn$11.5bn$8.2bn$5.4bn$6.2bn
+ Net debt (− = net cash)$1.1bn$502m$1.9bn$1.8bn$1.6bn$2.1bn$1.4bn$1.4bn$1.6bn$1.4bn$2.3bn$2.5bn
Enterprise value$7.0bn$7.7bn$12.9bn$13.3bn$18.6bn$20.8bn$16.4bn$12.9bn$13.1bn$9.6bn$7.7bn$8.7bn
Multiples
Price / sales 3.3x3.9x5.1x4.7x6.5x7.4x5.3x4.1x6.7x4.8x2.7x2.8x
Price / earnings 24.1x30.5x72.1x57.4x36.8x55.8x30.9x31.5x32.3x118.0x——
Price / free cash flow 24.4x20.2x31.0x32.5x50.7x54.0x25.9x43.4x72.0x38.9xn/m36.9x
EV / EBITDA 15.9x17.3x24.3x24.9x28.8x32.0x19.0x17.6x32.2x36.3x26.0x45.3x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

66 /100

Moderate moat

How hard Teleflex's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 9 / 20

    Cash operating profit has been a median 7.9% of total assets over 10 years.

  • Pricing power 16 / 20

    Gross margin has been a median 55.0%, moving by 4.5 percentage points (standard deviation) across 10 years.

  • Durability 5 / 20

    Operating margin has been a median 16.6%; its worst year was -1.9%.

  • Cash conversion 17 / 20

    Free cash flow was positive in 10 of 10 years, at a median 13.8% of revenue.

  • Discipline 19 / 20

    The diluted share count fell 6.8% over five years; stock-based pay has been a median 0.9% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 5, 2026, before the open. Analysts expect revenue of $565m and EPS of $1.89 (range $1.76 to $2.04) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $7.08 +1% $2.3bn +14%
Next $10.94 +55% $2.4bn +4%

Next year's EPS estimate has moved +3.4% in 90 days, across 12 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +6.0% on 90 days ago. In the last 30 days, 0 analysts raised Teleflex Inc's forecast and 1 cut it.

Consensus EPS forecast Teleflex Inc, last 90 days
$6.00 $8.00 $10.00 $12.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $6.68 Current fiscal year, 60 days ago: $7.08 Current fiscal year, 30 days ago: $7.08 Current fiscal year, 7 days ago: $7.08 Current fiscal year, Now: $7.08 $7.08 Next fiscal year, 90 days ago: $10.58 Next fiscal year, 60 days ago: $10.95 Next fiscal year, 30 days ago: $10.95 Next fiscal year, 7 days ago: $10.94 Next fiscal year, Now: $10.94 $10.94

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $6.68$10.58
60 days ago $7.08$10.95
30 days ago $7.08$10.95
7 days ago $7.08$10.94
Now $7.08$10.94

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $1.28 $1.76 +37.4%
Mar 2026 $1.21 $1.39 +14.5%
Dec 2025 $3.75 $1.93 −48.5%
Sept 2025 $3.38 $3.67 +8.6%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 6, 2026
  • GAAP revenue growth from continuing operations full year 2026 13.4% growth to 14.4% growth GAAP Lowered
    “On a GAAP basis, the Company reduced its full year 2026 revenue growth from continuing operations outlook to 13.40% to 14.40%, including our estimate of an approximately 0.70% positive impact of foreign exchange rate fluctuations.” source
  • Pro forma adjusted constant currency revenue growth from continuing operations full year 2026 3.5% growth to 4.5% growth Non-GAAP Lowered
    “On a pro forma adjusted constant currency basis, the Company reduced its full year 2026 revenue growth from continuing operations outlook to 3.50% to 4.50%.” source
  • GAAP diluted earnings per share from continuing operations full year 2026 $2.54 to $2.84 GAAP Lowered
    “The Company reduced its full year 2026 GAAP diluted earnings per share from continuing operations outlook range of $2.54 to $2.84.” source
  • Adjusted diluted earnings per share from continuing operations full year 2026 $6.90 to $7.20 Non-GAAP Raised
    “The Company increased its full year 2026 adjusted diluted earnings per share from continuing operations outlook to $6.90 to $7.20.” source
  • Adjusted operating margin 2026 about 19% Non-GAAP
    “Includes an assumption of approximately 19% adjusted operating margin for 2026 inclusive of transition services ("TS") associated with the close of the OEM Strategic Divestiture” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

Analyst recommendations

12 analysts, Oct 2026
Buy650%
Hold650%
Sell00%

Monthly trend

  1. Oct 202642612
  2. Sep 202642713
  3. Aug 202641813
  4. Jul 202641813

Counts of recommendations published by analysts covering Teleflex Inc, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
15.6%
of tradable shares
Days to cover
4.99
at average volume
Short interest, 1 month
+5%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
0.6%
of shares
Employees
15,500
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

What moved the share price

Last 12 months +14.3%

$123.10 on October 31, 2025 to $140.67

ThenNowEffect
Revenue (last 12 months) $1.7bn $2.3bn +30.7%
P/S multiple 3.3x 2.8x −16.0%
Share count 46m 44m +4.1%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

Last 3 years −31.5%

$205.39 on November 3, 2023 to $140.67

ThenNowEffect
Revenue (last 12 months) $2.9bn $2.3bn −22.2%
P/S multiple 3.3x 2.8x −17.8%
Share count 47m 44m +7.1%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
TFX−20%−24%+1%−28%−31%+16%
Industry peers (median)−7%−37%−9%−19%−16%−15%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
TFX33%50%50%50%50%64%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
TFX−35%−47%−34%−32%−43%−21%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since October 29, 2015: 77% from April 28, 2021 to January 20, 2026. Getting back needed a 329% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$99.54 – $142.05
From 52-week high
−1.0%
vs 50-day average
+7.1%
vs 200-day average
+12.6%
Volatility (1 year)
40%
Beta vs S&P 500
0.61

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
4 up, 8 down
typical move ±8.6%
After a week
5 up, 7 down
typical move ±9.0%
After a month
6 up, 6 down
typical move ±10.0%
Results releasedNext dayS&P 500 next day5 days21 days
August 6, 2026 −1.3% +0.5% +0.4% +1.4%
May 7, 2026 +8.0% +0.5% +5.7% +7.2%
February 26, 2026 +9.1% −1.0% +5.1% +4.2%
January 8, 2026 −10.8% +0.7% −17.3% −16.1%
November 6, 2025 −12.3% −1.0% −12.3% −3.7%
July 31, 2025 +1.7% −2.0% +1.4% +11.3%
May 1, 2025 −7.8% +2.2% −7.9% −12.5%
February 27, 2025 −25.3% −0.1% −23.3% −22.2%
October 31, 2024 −10.2% −1.5% −15.8% −17.2%
August 1, 2024 +7.3% −3.3% +4.1% +11.1%
May 2, 2024 −4.0% +2.2% −3.2% +1.8%
February 22, 2024 −5.3% +2.1% −11.1% −11.8%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Teleflex Inc in five measures

Fundamentals grade B
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Teleflex Inc
$0 $1B $2B $3B FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $3B Revenue (TTM), FY23 Q4: $1.7B Revenue (TTM), FY24 Q1: $1.4B Revenue (TTM), FY24 Q2: $1.1B Revenue (TTM), FY24 Q3: $769.4M Revenue (TTM), FY24 Q4: $1.7B Revenue (TTM), FY25 Q1: $1.7B Revenue (TTM), FY25 Q2: $1.7B Revenue (TTM), FY25 Q3: $1.9B Revenue (TTM), FY25 Q4: $2B Revenue (TTM), FY26 Q1: $2.1B Revenue (TTM), FY26 Q2: $2.3B $2.3B

Source: SEC EDGAR filings. Retrieved October 20, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $3B
FY23 Q4 $1.7B
FY24 Q1 $1.4B
FY24 Q2 $1.1B
FY24 Q3 $769.4M
FY24 Q4 $1.7B
FY25 Q1 $1.7B
FY25 Q2 $1.7B
FY25 Q3 $1.9B
FY25 Q4 $2B
FY26 Q1 $2.1B
FY26 Q2 $2.3B
Revenue growth, TTM YoY Teleflex Inc
-100% 0% 100% 200% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 5.9% Revenue growth, TTM YoY, FY23 Q4: -38.6% Revenue growth, TTM YoY, FY24 Q1: -50.6% Revenue growth, TTM YoY, FY24 Q2: -62.4% Revenue growth, TTM YoY, FY24 Q3: -74.0% Revenue growth, TTM YoY, FY24 Q4: -0.8% Revenue growth, TTM YoY, FY25 Q1: 20.3% Revenue growth, TTM YoY, FY25 Q2: 58.3% Revenue growth, TTM YoY, FY25 Q3: 142.5% Revenue growth, TTM YoY, FY25 Q4: 17.2% Revenue growth, TTM YoY, FY26 Q1: 25.0% Revenue growth, TTM YoY, FY26 Q2: 30.7% 30.7%

Source: SEC EDGAR filings. Retrieved October 20, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 5.9%
FY23 Q4 -38.6%
FY24 Q1 -50.6%
FY24 Q2 -62.4%
FY24 Q3 -74.0%
FY24 Q4 -0.8%
FY25 Q1 20.3%
FY25 Q2 58.3%
FY25 Q3 142.5%
FY25 Q4 17.2%
FY26 Q1 25.0%
FY26 Q2 30.7%
Operating margin (TTM) Teleflex Inc
-20% -10% 0% 10% 20% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: 18.7% Operating margin (TTM), FY23 Q4: 15.1% Operating margin (TTM), FY24 Q1: 5.1% Operating margin (TTM), FY24 Q2: -1.9% Operating margin (TTM), FY24 Q3: -14.8% Operating margin (TTM), FY24 Q4: 6.1% Operating margin (TTM), FY25 Q1: 14.8% Operating margin (TTM), FY25 Q2: 16.9% Operating margin (TTM), FY25 Q3: 8.4% Operating margin (TTM), FY25 Q4: 5.9% Operating margin (TTM), FY26 Q1: 3.0% Operating margin (TTM), FY26 Q2: 2.0% 2.0%

Source: SEC EDGAR filings. Retrieved October 20, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 18.7%
FY23 Q4 15.1%
FY24 Q1 5.1%
FY24 Q2 -1.9%
FY24 Q3 -14.8%
FY24 Q4 6.1%
FY25 Q1 14.8%
FY25 Q2 16.9%
FY25 Q3 8.4%
FY25 Q4 5.9%
FY26 Q1 3.0%
FY26 Q2 2.0%
FCF margin (TTM) Teleflex Inc
-10% 0% 10% 20% 30% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: 12.9% FCF margin (TTM), FY23 Q4: 9.3% FCF margin (TTM), FY24 Q1: 12.1% FCF margin (TTM), FY24 Q2: 14.7% FCF margin (TTM), FY24 Q3: 25.0% FCF margin (TTM), FY24 Q4: 12.4% FCF margin (TTM), FY25 Q1: 8.3% FCF margin (TTM), FY25 Q2: 1.1% FCF margin (TTM), FY25 Q3: -1.9% FCF margin (TTM), FY25 Q4: 0.1% FCF margin (TTM), FY26 Q1: 1.2% FCF margin (TTM), FY26 Q2: 7.5% 7.5%

Source: SEC EDGAR filings. Retrieved October 20, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 12.9%
FY23 Q4 9.3%
FY24 Q1 12.1%
FY24 Q2 14.7%
FY24 Q3 25.0%
FY24 Q4 12.4%
FY25 Q1 8.3%
FY25 Q2 1.1%
FY25 Q3 -1.9%
FY25 Q4 0.1%
FY26 Q1 1.2%
FY26 Q2 7.5%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2009 Dec 2009 2010 Dec 2010 2011 Dec 2011 2012 Dec 2012 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 1,435 1,398 1,493 1,551 1,696 1,840 1,810 1,868 2,146 2,448 2,595 2,537 2,810 2,791 1,712 1,700 1,993 2,255
Gross profit 686 679 709 748 839 942 944 996 1,172 1,303 1,409 1,325 1,550 1,531 1,040 1,037 1,121 1,239
EBITDA 297 320 326 −2 341 412 441 448 533 536 646 650 865 730 407 265 296 193
Operating income 250 230 230 −97 233 285 316 319 372 322 427 423 628 500 259 104 118 44
Net income 303 201 323 −190 151 188 245 237 153 201 461 335 485 363 356 70 −906 −1,032
Diluted EPS $7.59 $4.99 $7.92 −$4.65 $3.45 $4.04 $5.10 $4.98 $3.27 $4.29 $9.80 $7.09 $10.23 $7.68 $7.53 $1.48 −$20.25 −$23.37
Growth (year on year)
Revenue −25.0% −2.6% +6.8% +3.9% +9.4% +8.5% −1.6% +3.2% +14.9% +14.1% +6.0% −2.2% +10.7% −0.7% −38.6% −0.8% +17.2% +30.7%
EBITDA +0.8% +7.6% +1.9% −100.8% — +20.7% +7.1% +1.5% +18.9% +0.7% +20.4% +0.7% +33.1% −15.6% −44.3% −34.8% +11.7% −51.1%
Operating income +4.7% −8.0% −0.3% −142.4% — +22.1% +10.9% +1.1% +16.5% −13.6% +32.8% −1.0% +48.5% −20.4% −48.2% −59.9% +14.2% −84.7%
Net income +153.0% −33.6% +60.8% −158.8% — +24.4% +30.5% −3.1% −35.7% +31.6% +129.8% −27.3% +44.7% −25.2% −1.9% −80.4% <−999% −637.5%
Diluted EPS +152.2% −34.3% +58.7% −158.7% — +17.1% +26.2% −2.4% −34.3% +31.2% +128.4% −27.7% +44.3% −24.9% −2.0% −80.3% <−999% −659.8%
Margins
Gross margin 47.8% 48.6% 47.5% 48.2% 49.5% 51.2% 52.2% 53.3% 54.6% 53.2% 54.3% 52.2% 55.2% 54.9% 60.7% 61.0% 56.2% 54.9%
EBITDA margin 20.7% 22.9% 21.8% −0.2% 20.1% 22.4% 24.4% 24.0% 24.8% 21.9% 24.9% 25.6% 30.8% 26.2% 23.8% 15.6% 14.9% 8.5%
Operating margin 17.4% 16.5% 15.4% −6.3% 13.8% 15.5% 17.5% 17.1% 17.3% 13.1% 16.5% 16.7% 22.4% 17.9% 15.1% 6.1% 5.9% 2.0%
Net margin 21.1% 14.4% 21.7% −12.3% 8.9% 10.2% 13.5% 12.7% 7.1% 8.2% 17.8% 13.2% 17.3% 13.0% 20.8% 4.1% −45.4% −45.8%
Free-cash-flow margin 6.5% 8.2% 3.3% 8.3% 9.9% 12.1% 13.4% 19.1% 16.6% 14.5% 12.9% 13.7% 20.7% 9.4% 9.3% 12.4% 0.1% 7.5%
Cash flow
Cash from operations 120 144 94 195 231 290 303 411 426 435 437 437 652 343 206 302 97 245
Capital spending 26 29 45 65 64 68 61 53 71 81 103 91 72 79 46 90 95 76
Free cash flow 94 115 50 129 168 223 242 357 355 354 334 346 581 264 160 211 1 168
Stock-based pay 8 9 5 9 12 12 14 17 19 22 27 21 23 27 27 26 26 26
Free cash flow after stock pay 86 106 45 121 156 210 228 341 336 332 307 326 558 236 132 185 −24 143
Balance sheet
Cash 188 208 584 337 432 303 338 544 334 357 301 376 445 292 223 248 379 300
Total debt 1,196 1,237 1,290 1,025 1,643 1,437 1,479 1,046 2,270 2,177 1,923 2,498 1,864 1,723 1,825 1,663 2,650 2,825
Net debt (negative = net cash) 1,008 1,029 706 688 1,211 1,134 1,141 502 1,936 1,819 1,622 2,122 1,418 1,431 1,602 1,415 2,271 2,525
Diluted shares 40m 40m 41m 41m 44m 46m 48m 48m 47m 47m 47m 47m 47m 47m 47m 47m 45m 44m
Returned to shareholders
Dividends 54 54 55 56 56 56 57 59 61 62 63 63 64 64 64 64 60 60
Buybacks — — — — — — — — — — — — — 0 0 200 300 250
Total returned 54 54 55 56 56 56 57 59 61 62 63 63 64 64 64 264 360 310

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

1 of 7 checks passed · June 30, 2026
What it owns · $6.8bn
Short-term assets $1.9bnLonger-term assets $4.9bn
What it owes, and who funded it · $6.8bn
Short-term liabilities $720mLonger-term liabilities $3.2bnShareholders' equity $2.9bn
  • Short-term assets cover short-term liabilities $1.9bn of assets due within a year against $720m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $1.9bn short-term assets against $3.2bn of longer-dated liabilities.
  • More cash than debt $300m of cash against $2.8bn of debt.
  • Debt below 40% of shareholders' equity Debt is 97% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 46% to 97% over five years.
  • A year's operating cash flow covers at least 20% of debt $245m of operating cash flow against $2.8bn of debt.
  • Operating profit covers interest at least five times over Operating income of $44m against $114m of interest.

From Teleflex Inc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2026 Q2 TTM
Buybacks (TTM)
$250M
Dividends (TTM)
$59.9M
Returned to shareholders
184%
of free cash flow
Buybacks, last 3 fiscal years
$500M
Diluted share count
−4.0%
year over year
Total shareholder yield
5.0%
dividends 1.0% + buybacks 4.1% of market value
R&D spending
7.1%
of revenue
Sales & admin spending
32.0%
of revenue
Days sales outstanding
59 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care equipment
Last 12 months unless stated TFX ENOV QDEL ITGR RVTY PODD Median
Revenue, last 12 months $2.3bn $2.3bn $2.7bn $1.8bn $2.9bn $3.1bn $99m
Revenue growth, last 12 months 30.7% 4.9% −2.5% −0.3% 4.1% 29.4% 9.2%
Revenue growth, 3-year average −8.0% 12.2% −5.4% 6.7% 0.9% 27.7% 13.5%
Revenue growth, latest quarter 28.9% 3.2% 2.8% −3.9% 1.3% 23.5% 10.2%
Gross margin 54.9% 61.1% — 24.6% 60.1% 71.1% 61.2%
Operating margin 2.0% −45.1% −30.8% 8.2% 12.3% 16.9% −8.5%
Operating margin, 3-year average 5.7% −28.5% −34.4% 10.7% 12.0% 16.2% −17.9%
Net margin −45.8% −48.0% −39.2% 5.7% 8.2% 12.3% −12.0%
Cash from operations / revenue 10.8% 11.8% −2.1% 9.7% 21.6% 16.7% −1.9%
Free-cash-flow margin 7.5% 2.8% −7.9% 4.5% 19.2% 9.0% −3.9%
Free-cash-flow margin, 3-year average 7.7% −0.2% −4.5% 5.2% 17.1% 11.6% −7.0%
Stock pay / revenue 1.1% 1.5% 1.7% 1.3% 0.3% 2.6% 6.1%
Change in share count −4.0% 1.7% 0.9% −0.8% −6.2% −3.6% 4.0%

Median of all 134 companies we cover in health care equipment. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

134 health care equipment companies
Measure Company Peer median Rank
Revenue growth Growth 30.7% 9.1% 25 of 129
Change in growth rate Growth +5.7pp -0.6pp 22 of 129
Gross margin Profitability 54.9% 61.9% 80 of 123
Operating margin Profitability 2.0% -8.3% 45 of 132
Net margin Profitability -45.8% -12.0% 86 of 133
Free-cash-flow margin Cash generation 7.5% -3.4% 38 of 128
Stock pay as % of revenue Cash generation 1.1% 6.1% 11 of 123
Long-term debt as % of assets Balance sheet 40.1% 24.2% 69 of 87
Change in share count Balance sheet -4.0% 3.3% 9 of 115
Days sales outstanding Balance sheet 59 days 57 days 65 of 118

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Segments
Line of business Revenue Share YoY
Americas $1.3B 64.2% ▲ 10.6%
EMEA $472M 23.7% ▲ 38.8%
Asia $241M 12.1% ▲ 19.2%
Products and services
Line of business Revenue Share YoY
Vascular Access $918M 46.1% ▲ 1.6%
Interventional $648M 32.5% ▲ 63.0%
Surgical $418M 21.0% ▲ 3.3%
Other $9M 0.5% —
Geography
Region Revenue Share YoY
United States $1.2B 59.3% ▲ 9.5%
Europe $485M 24.3% ▲ 39.3%
Asia and Asia Pacific $218M 10.9% ▲ 21.4%
All Other $108M 5.4% ▲ 16.6%

From Teleflex Inc's 10-K filed February 27, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$6.1B
Institutions reporting
381
Shares held vs prior quarter
▲ 0.2%
Positions opened / closed
62 / 49

Top buyers and sellers, Q2 2026: 190 institutions bought and 180 sold ; the biggest buyer was Millennium Management LLC (+760K shares) and the biggest seller Point72 Asset Management, L.P (−677K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $689M 5.4M 11.3% ▲ 0.7%
Jupiter Topco LLC $550M 4.3M 9.1% —
T. Rowe Price Investment Management, Inc. $405M 3.2M 6.7% ▼ 16.7%
Vanguard Portfolio Management LLC $306M 2.4M 5.0% ▼ 0.9%
Vanguard Capital Management LLC $253M 2.0M 4.2% ▲ 0.6%
Sessa Capital Im, L.P. $193M 1.5M 3.2% 0.0%
State Street Corp $188M 1.5M 3.1% ▼ 1.3%
Millennium Management LLC $183M 1.4M 3.0% ▲ 111.4%
Baupost Group LLC $179M 1.4M 2.9% ▼ 11.7%
Fuller & Thaler Asset Management, Inc. $167M 1.3M 2.8% ▼ 3.2%
Dimensional Fund Advisors LP $146M 1.2M 2.4% ▲ 15.6%
Citadel Advisors LLC $145M 1.1M 2.4% ▼ 2.6%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Teleflex Inc's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 22 trades and filings

No trades in Teleflex Inc disclosed in the last 12 months; 22 earlier trades on record.

  • Lisa C. McClain(R-MI 9):Sale (full), $1,001 - $15,000, traded July 22, 2025, filed August 13, 2025
  • Lisa C. McClain(R-MI 9):Purchase, $1,001 - $15,000, traded July 16, 2025, filed August 13, 2025
  • Robert P. Bresnahan, Jr.(R-PA 8):Sale (full), $1,001 - $15,000, traded February 25, 2025, filed March 27, 2025

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around October 25, 2026 estimated from the company's past filing pattern, not announced

  • August 6, 2026
  • May 7, 2026
  • February 26, 2026
  • January 8, 2026
  • November 6, 2025
  • July 31, 2025

Recent SEC filings

Data status

When each part of this page on Teleflex Inc was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Teleflex Inc in brief

What does Teleflex Inc do?
Teleflex Inc is a US-listed company in the health care equipment industry. Its financial year ends in December.
What is Teleflex Inc's stock ticker?
Teleflex Inc trades under the ticker TFX on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Teleflex Inc's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Teleflex Inc reported revenue of $2.3B, 30.7% higher than a year earlier, according to its SEC filings.
What is Teleflex Inc's free cash flow?
Teleflex Inc's free-cash-flow margin is 7.5% of revenue over the trailing twelve months, ranking 38 of the 128 health care equipment companies we cover.
Who are Teleflex Inc's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Jupiter Topco LLC and T. Rowe Price Investment Management, Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is Teleflex Inc buying back stock, and does it pay a dividend?
Teleflex Inc spent $250M on share repurchases over the trailing twelve months, and its diluted share count fell 4.0% over the year.
What is Teleflex Inc's market cap?
On November 2, 2026, Teleflex Inc's market capitalisation was about $6.2B and net debt of $2.5B. Market figures come from third-party market data and may be delayed.
Does Teleflex Inc pay a dividend?
Yes: Teleflex Inc paid $59.9M in dividends over the trailing twelve months, a dividend yield of 0.97%.
How much debt does Teleflex Inc have?
Teleflex Inc's debt-to-equity ratio is 96.7%, from its latest balance sheet (46.3% five years earlier). The financial health section below sets out its other solvency checks.
Who are Teleflex Inc's competitors?
In our Health Care Equipment peer group, the companies closest to Teleflex Inc are Enovis Corp, Quidelortho Corp, Integer Holdings Corp, Revvity and Insulet Corporation. The side-by-side comparison below sets their revenue, margins and growth against Teleflex Inc's.
When is Teleflex Inc's next earnings date?
Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Teleflex Inc announces its own schedule.